Triptorelin vs HCG

Triptorelin and hCG both act on the HPG axis but from opposite directions, making them suited for distinct research contexts. Triptorelin is a decapeptide GnRH agonist (MW ~1311.4 g/mol) that initially triggers gonadotropin release then suppresses it via receptor downregulation. HCG is a larger glycoprotein hormone (MW ~36,700 g/mol) that binds LH/CG receptors to stimulate sex steroid production. Their FDA-approved indications—triptorelin for prostate cancer and central precocious puberty; hCG for infertility and periovulatory triggers—reflect these mechanistic differences. In preclinical models, triptorelin is often used to model hypogonadotropic states, while hCG serves to evaluate Leydig cell function or luteal support. Their shared research application in reproductive health belies fundamentally different intended effects, making direct comparison essential for protocol design.

Triptorelin's mechanism hinges on sustained GnRH receptor activation. Research demonstrates that initial agonist binding stimulates LH and FSH release (the flare phase), lasting 1–2 weeks, after which receptor desensitization and downregulation reduce gonadotropin secretion to castrate levels. This dual-phase action is leveraged in prostate cancer models to achieve androgen suppression, with depot formulations allowing monthly to semiannual dosing (3.75–22.5 mg). Studies in precocious puberty confirm rapid hypothalamic-pituitary suppression, halting pubertal progression. Compared to other GnRH agonists (leuprolide, goserelin), triptorelin shows comparable efficacy but distinct pharmacokinetics due to its D-Trp substitution enhancing receptor binding. Evidence quality is high for its approved indications, though research also explores its use in endometriosis, uterine fibroids, and transgender care. Key tradeoffs: the mandatory flare period can exacerbate androgen-dependent conditions, and long-term use induces menopausal-like estrogen deficiency.

Human chorionic gonadotropin mimics luteinizing hormone by binding with high affinity to the LH/CG receptor. Its larger size and unique beta subunit confer a longer circulating half-life (~24 h) than pituitary LH, enabling sustained stimulation of Leydig cells (testosterone) and corpus luteum (progesterone). Evidence for its role in maintaining testicular function during testosterone replacement therapy is robust: studies indicate hCG preserves intratesticular testosterone and spermatogenesis, reducing testicular atrophy. In fertility research, hCG triggers final oocyte maturation and luteinization, a standard for IVF protocols. Off-label use also includes cryptorchidism and hypogonadotropic hypogonadism. Compared to recombinant LH, hCG provides longer action at lower cost but carries higher estradiol conversion risk (gynecomastia, fluid retention). Research context varies: short-term use for ovulation trigger versus chronic low-dose for fertility preservation. The evidence base is strong for reproductive indications, but caution is warranted regarding ovarian hyperstimulation syndrome (OHSS), a potentially serious adverse effect.

Both peptides are investigated in reproductive endocrinology, yet their roles are nearly opposite. Triptorelin is studied for controlled ovarian downregulation in IVF—suppressing endogenous LH surges to prevent premature ovulation—whereas hCG is used to trigger final follicular maturation. Preclinical models of reproductive aging may employ triptorelin to induce hypogonadotropic states, while hCG tests Leydig cell responsiveness. Beyond reproduction, triptorelin appears in cancer research (androgen suppression) and hCG in hormonal studies (stimulation of steroidogenesis). Their overlap is minimal: they target different nodes of the HPG axis. Researchers choose triptorelin when sustained suppression is needed (e.g., to create a reversible chemical castration model) and hCG when direct gonadal stimulation is desired (e.g., to evaluate recovery of testicular function). Selection depends on whether the research question involves feedback downregulation or exogenous agonist activity.

Triptorelin carries unique risks due to its flare effect: in prostate cancer models, initial androgen surge can exacerbate bone pain and urinary obstruction (occurring in 5–10% of treated patients). Long-term suppression leads to hot flashes (58–73%), erectile dysfunction, and decreased libido from estrogen deficiency. Depot injections may cause injection-site abscesses. HCG's safety profile is primarily linked to sex steroid conversion: gynecomastia and water retention in males; OHSS in females (mild in 10–20%, severe in 0.1–2%). Common side effects include injection-site reactions, headache, and fatigue. Research suggests HCG does not suppress endogenous LH, so recovery after cessation is faster than with triptorelin. Both require monitoring of hormone levels and clinical response. For researchers, the choice involves weighing triptorelin's potent suppression with its obligate flare and hypoestrogenic effects against hCG's stimulatory action with risk of estrogenic adverse events and OHSS.